Patents Assigned to UROVANT SCIENCES GMBH
  • Publication number: 20220133849
    Abstract: The present disclosure provides compositions and methods to treat diseases and conditions related to smooth muscle dysfunction, or to ameliorate symptoms thereof comprising gene therapy, wherein one or more polynucleotides encoding one or more subunits of the Maxi-K channel, or mutants, variants, functional fragments, or derivatives thereof (e.g., fusions and chimaeras) are administered to a subject in need thereof, and wherein the administration of the polypeptides result in the expression of functional Maxi-K channels in the targeted smooth muscle. In some aspects, the composition of the disclosure comprise plasmid vectors containing at least one nucleic acid encoding a Maxi-K channel peptide. Also disclosed are pharmaceutical compositions, articles or manufacture, and kits.
    Type: Application
    Filed: November 14, 2019
    Publication date: May 5, 2022
    Applicant: UROVANT SCIENCES GMBH
    Inventor: Arnold MELMAN
  • Publication number: 20210196720
    Abstract: The present disclosure is directed to a method of treating or preventing pain associated with irritable bowel syndrome comprising orally administering to a subject in need thereof vibegron.
    Type: Application
    Filed: May 23, 2019
    Publication date: July 1, 2021
    Applicant: UROVANT SCIENCES GMBH
    Inventors: Paul N. MUDD, JR., Cornelia HAAG-MOLKENTELLER, Jihao ZHOU, Chris SCHAUMBURG, Jean Paul Abrian NICANDRO